October 1, 2007 - DiaMedica Inc. (TSX-V:DMA), a drug discovery and development company focused on novel treatments for type 2 diabetes, is pleased to announce exciting results for DM-71 in its proof-of-concept phase II clinical study in type 2 diabetes... DiaMedica's Press Release -
Blog Archive
-
▼
2007
(88)
-
▼
October
(25)
- SemBioSys, insulin data
- Synvista's Alagebrium, Potential for use in Treati...
- Isis, New Drug to Its Development Pipeline: ISIS 3...
- Lilly and MacroGenics, Licensing and Collaboratio...
- Flamel Technologies, Positive Results of a Phase I...
- Generex Biotechnology, Contract Research Organizat...
- DARA BioSciences and Bayer Pharmaceuticals, Exclus...
- Merck , Supplemental New Drug Applications for JAN...
- Johnson & Johnson, Global Diabetes Institute
- Exelixis, Results of the Phase 2 Trial of XL784 in...
- Hollis-Eden Pharmaceuticals, Phase I/II Clinical T...
- Living Cell Technologies, Positive Preliminary Dat...
- Isis, $1.25 Million Milestone Payment From iCo for...
- Johnson & Johnson Pharmaceutical R & D, Ceftobipro...
- Akesis Pharmaceuticals , IND for Phase IIa Trial o...
- Alimera Sciences and pSivida , Pivotal Phase 3 Tri...
- MyCareTeam, New Diabetes Tool Available on ADA We...
- VERICHIP and DIGITAL ANGEL, IMPLANTABLE RFID GLUCO...
- HMM , Blood Glucose Meter for Self-Monitoring With...
- Home Diagnostics on Microsoft HealthVault
- Phylonix Phase II SBIR to Develop Zebrafish Models...
- CardioVascular BioTherapeutics, Phase I Wound Heal...
- Generex Biotechnology, new United States Patent
- DiaMedica, phase II results for DM-71 in type 2 di...
- Novartis, Galvus European approval as new treatmen...
-
▼
October
(25)
Tuesday, October 2, 2007
DiaMedica, phase II results for DM-71 in type 2 diabetes trial
October 1, 2007 - DiaMedica Inc. (TSX-V:DMA), a drug discovery and development company focused on novel treatments for type 2 diabetes, is pleased to announce exciting results for DM-71 in its proof-of-concept phase II clinical study in type 2 diabetes... DiaMedica's Press Release -
